2016 Half-Year Results

Corporate Pharma&Biotech Financials HY 2016 Lonza Key Figures CORE EBITDA and Margin Progression 300 30% CHF mn HY 2016 HY 2015 % YOY 27.0% 24.8% 23.8% 24.1% 25% Sales 838 754 11.1 200 226 20% 182 15% CORE EBITDA 226 182 24.2 167 145 100 10% Margin 27.0% 24.1% 5% CORE EBIT 159 Margin 19.0% 117 15.5% 35.9 0 0% HY 2013 HY 2014 HY 2015 HY 2016 CORE EBITDA (CHF million) CORE EBITDA margin (%) ■Strong performance driven by outstanding operational performance across all assets ■Particular momentum coming from the Commercial Mammalian Manufacturing business ■Made-to-stock Bioscience Solutions business with strong growth in sales and profits ■Excellent performance expected to continue also in the second half CORE definition: see appendix 2016 Half-Year Results - 20 July 2016 8 Jul-16

View entire presentation